Role of antibody-secreting cells as early biomarkers of immune response to influenza vaccination in rheumatoid arthritis patients treated with anti-TNF agents

International Journal of Clinical Rheumatology

Volumn 7, Issue 2, 2012, Pages 155-158

  Salemi, Simonetta ^a   Germano, Valentina ^a   Diamanti, Andrea Picchianti ^a   D'Amelio, Raffaele ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

antibody response; biomarkers; effector B cells; influenza vaccine; memory B cells; rheumatoid arthritis; TNF antagonists

Indexed keywords

CORTICOSTEROID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CYTOKINE PRODUCTION; EFFECTOR B CELL; EFFECTOR CELL; GERMINAL CENTER; HUMAN; INFLUENZA VACCINATION; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE SUBPOPULATION;

EID: 84859406457     PISSN: 17584272     EISSN: 17584280     Source Type: Journal    
DOI: 10.2217/ijr.12.8     Document Type: Article

References (18)

1. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin. Arthritis Rheum. 39(5), 327-346 (2010).
2. Salemi S, D'Amelio R. Are anti-infectious vaccinations safe and effective in patients with autoimmunity? Int. Rev. Immunol. 29(3), 270-314 (2010).
3. Gabay C, Bel M, Combescure C et al. H1N1 study group. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic infuenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum. 63(6), 1486-1496 (2011).
4. Elkayam O, Amir S, Mendelson E et al. Effcacy and safety of vaccination against pandemic 2009 infuenza A (H1N1) virus among patients with rheumatic diseases Arthritis Care Res. (Hoboken) 63(7), 1062-1067 (2011).
5. Kobie JJ, Zheng B, Bryk P et al. Decreased infuenza-specifc B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. Arthritis Res. Ther. 13, R209 (2011).
6. Carsetti R, Rosado MM, Donnanno S. The loss of IgM memory B cells correlates with clinical disease in common variable immunodefciency. J. Allergy Clin. Immunol. 115(2), 412-417 (2005). (Pubitemid 40215112)
7. He XS, Sasaki S, Narvaez CF et al. Plasmablast-derived polyclonal antibody response after infuenza vaccination. J. Immunol. Methods 365(1-2), 67-75 (2011).
8. Anolik JH, Ravikumar R, Barnard J et al. Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J. Immunol. 180(2), 688-692 (2008).
9. Fahy WA, Farnworth E, Yeldrem KP et al. Pneumococcal and infuenza vaccination in patients with rheumatic conditions and receiving DMARD therapy. Rheumatology (Oxf.). 45(7), 912-913 (2006). (Pubitemid 43985385)
10. van Assen S, Agmon-Levin N, Elkayam O et al. EULAR recommendations for vaccination in adult patients with autoimmune infammatory rheumatic diseases. Ann. Rheum. Dis. 70(3), 414-422 (2011).
11. Kapetanovic MC, Saxne T, Nilsson JA, Geborek P. Infuenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxf.). 46(4), 608-611 (2007). (Pubitemid 46523304)
12. Baldo V, Baldovin T, Floreani A et al. Family medicine group. Response of infuenza vaccines against heterovariant infuenza virus strains in adults with chronic diseases. J. Clin. Immunol. 27(5), 542-547 (2007). (Pubitemid 47319253)
13. Salemi S, Picchianti-Diamanti A, Germano V et al. Infuenza vaccine administration in rheumatoid arthritis patients under treatment with TNFa blockers: safety and immunogenicity. Clin. Immunol. 134(2), 113-120 (2010).
14. + T-regulatory cells on the B and T helper cell responses to infuenza virus vaccination. Vaccine 28(45), 7319-7330 (2010).
15. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-a therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-b. J. Exp. Med. 22, 204(1), 33-39 (2007). (Pubitemid 46148753)
16. + T cell response against infuenza. Vaccine 30(9), 1659-1666 (2012).
17. Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax 55(7), 603-613 (2000). (Pubitemid 30398277)
18. Strangfeld A, Eveslage M, Schneider M et al. Treatment beneft or survival of the fttest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann. Rheum. Dis. 70(11), 1914-1920 (2011).